A recombinant protein comprising multiple multi-peptide sets includes first through fifth sequencing primers and first through fourth multi-peptide regions. The first multi-peptide region is between the first and the second sequencing primers. The second multi-peptide region is between the second and the third sequencing primers. The third multi-peptide region is between the third and the fourth sequencing primers. The fourth multi-peptide region is between the fourth and the fifth sequencing primers. In each of the multi-peptide regions, multiple functional peptides can be inserted, and manufacturing thereof can be done through expression of the recombinant protein, thereby significantly enhancing the concentrations of the functional peptides. With the combination of peptide having different functions, the recombinant protein product can provide more complete and more comprehensive functionality. This application also discloses a pharmaceutical composition comprising the recombinant protein and a method for preparing the recombinant protein.

A method and apparatus for the manufacture of disulfide bonded peptides is provided, wherein a solution of an oxidizing agent and a solution of a peptide comprising at least two sulfhydryl groups are added simultaneously into a reaction vessel under such conditions that the average concentration of the oxidizing agent inside the reaction vessel is essentially zero during simultaneous addition.

A method and apparatus for the manufacture of disulfide bonded peptides is provided, wherein a solution of an oxidizing agent and a solution of a peptide comprising at least two sulfhydryl groups are added simultaneously into a reaction vessel under such conditions that the average concentration of the oxidizing agent inside the reaction vessel is essentially zero during simultaneous addition.

The present disclosure relates to compounds of Formula I being cyclic metabolites of oxytocin. These derivatives have enhanced selectivity for the oxytocin receptor.

The present disclosure relates to compounds of Formula I being cyclic metabolites of oxytocin. These derivatives have enhanced selectivity for the oxytocin receptor.

The present invention relates to crystalline forms of carbetocin, a method of their manufacture, and pharmaceutical compositions thereof.

The present invention relates to crystalline forms of carbetocin, a method of their manufacture, and pharmaceutical compositions thereof.

This invention relates to drug delivery and in particular to the delivery of biologically active agents in the form of dry powders for inhalation. The invention also relates to methods for preparing such dry powder formulations and methods for their use.

This invention relates to drug delivery and in particular to the delivery of biologically active agents in the form of dry powders for inhalation. The invention also relates to methods for preparing such dry powder formulations and methods for their use.

In an aspect, disclosed herein is a compound characterized by formula (FX1): A.sup.1-X.sup.1—X.sup.2-A.sup.2 (FX1); wherein: A.sup.1 is a carboxylic acid group, a carboxylate anion, or a carboxylate ester, X.sup.1 is a substituted or unsubstituted and saturated or unsaturated C.sub.1-C.sub.50 aliphatic group; X.sup.2 is a linker group selected from the group consisting of a direct bond, an organic group, -0-, —S—, —S(═O)—, —S(═O).sub.2—, —S—S—, —N═, ═N—, —N(H)—, —N═N—N(H)—, —N(H)—N═N—, —N(OH)—, —N(═O)—, and any combination thereof; and A.sup.2 is a peptide, the peptide being terlipressin or a substituted or unsubstituted derivative, a substituted or unsubstituted natural or synthetic analogue, a substituted or unsubstituted variant, a substituted or unsubstituted isomer, or a substituted or unsubstituted fragment of terlipressin.